Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus LINAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus LINAGLIPTIN.
KOMBIGLYZE XR vs LINAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
5 mg orally once daily
None Documented
None Documented
Clinical Note
moderateLinagliptin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Delavirdine
"The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Clarithromycin
"The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin."
Clinical Note
moderateLinagliptin + Ranolazine
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Terminal elimination half-life is approximately 12 hours, allowing once-daily dosing. No accumulation at steady state.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Approximately 90% of absorbed dose is excreted unchanged in feces (biliary/fecal route), and about 5% is excreted unchanged in urine. Renal excretion is minimal (<1% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor
"The serum concentration of Ranolazine can be increased when it is combined with Linagliptin."